EPW
HQL

Evolve Private Wealth’s abrdn Life Sciences Investors HQL Stock Holding History

Evolve Private Wealth’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Buy
12,197
+443
+4% +$7.83K 0.01% 839
2026
Q1 		$191K Sell
11,754
-100
-0.8% -$1.67K 0.01% 941
2025
Q4 		$199K Buy
+11,854
New +$199K 0.01% 874

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Evolve Private Wealth's HQL Position: Q2 2026 in Review

Evolve Private Wealth increased its abrdn Life Sciences Investors (HQL) stake by 3.8% in Q2 2026, buying an estimated $7.83K and bringing the position to 12,197 shares worth $244K. The position accounts for 0.01% of the portfolio, ranked #839.

Evolve Private Wealth first reported a position in HQL in Q4 2025 and has held it in 3 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • Evolve Private Wealth held 12,197 shares of abrdn Life Sciences Investors worth $244K as of Q2 2026.
  • Evolve Private Wealth bought 443 abrdn Life Sciences Investors shares in Q2 2026, an estimated $7.83K.
  • abrdn Life Sciences Investors made up 0.01% of Evolve Private Wealth's portfolio in Q2 2026, its #839 holding.
  • Evolve Private Wealth first reported a position in abrdn Life Sciences Investors in Q4 2025 and has held it in 3 quarters since.
  • 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.